|
"shahidi mehdi"的相关文件
显示项目 1-9 / 9 (共1页)
1
每页显示[10|25|50]项目
| 國立臺灣大學 |
2015 |
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
|
Yang, James Chih-Hsin; Wu, Yi-Long; Schuler, Martin; Sebastian, Martin; Popat, Sanjay; Yamamoto, Nobuyuki; Zhou, Caicun; Hu, Cheng-Ping; O'Byrne, Kenneth; Feng, Jifeng; Lu, Shun; Huang, Yunchao; Geater, Sarayut L.; Lee, Kye Young; Tsai, Chun-Ming; Gorbunova, Vera; Hirsh, Vera; Bennouna, Jaafar; Orlov, Sergey; Mok, Tony; Boyer, Michael; Su, Wu-Chou; Lee, Ki Hyeong; Kato, Terufumi; Massey, Dan; Shahidi, Mehdi; Zazulina, Victoria; Sequist, Lecia V.; 楊志新 |
| 國立成功大學 |
2013-09-20 |
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
|
Sequist, Lecia V.; Yang, James Chih-Hsin; Yamamoto, Nobuyuki; O'Byrne, Kenneth; Hirsh, Vera; Mok, Tony; Geater, Sarayut Lucien; Orlov, Sergey; Tsai, Chun-Ming; Boyer, Michael; Su, Wu-Chou; Bennouna, Jaafar; Kato, Terufumi; Gorbunova, Vera; Lee, Ki Hyeong; Shah, Riyaz; Massey, Dan; Zazulina, Victoria; Shahidi, Mehdi; Schuler, Martin |
| 國立臺灣大學 |
2013 |
Symptom Control and Quality of Life in LUX-Lung 3: A Phase III Study of Afatinib or Cisplatin/Pemetrexed in Patients With Advanced Lung Adenocarcinoma With EGFR Mutations
|
Yang, James Chih-Hsin; Hirsh, Vera; Schuler, Martin; Yamamoto, Nobuyuki; O'Byrne, Kenneth J.; Mok, Tony S. K.; Zazulina, Victoria; Shahidi, Mehdi; Lungershausen, Juliane; Massey, Dan; Palmer, Michael; Sequist, Lecia V.; 楊志新 |
| 國立臺灣大學 |
2013 |
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
|
Sequist, Lecia V.; Yang, James Chih-Hsin; Yamamoto, Nobuyuki; O'Byrne, Kenneth; Hirsh, Vera; Mok, Tony; Geater, Sarayut Lucien; Orlov, Sergey; Tsai, Chun-Ming; Boyer, Michael; Su, Wu-Chou; Bennouna, Jaafar; Kato, Terufumi; Gorbunova, Vera; Lee, Ki Hyeong; Shah, Riyaz; Massey, Dan; Zazulina, Victoria; Shahidi, Mehdi; Schuler, Martin; 楊志新 |
| 國立成功大學 |
2012-05 |
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial
|
Miller, Vincent A.; Hirsh, Vera; Cadranel, Jacques; Chen, Yuh-Min; Park, Keunchil; Kim, Sang-We; Zhou, Caicun; Su, Wu-Chou; Wang, Mengzhao; Sun, Yan; Heo, Dae Seog; Crino, Lucio; Tan, Eng-Huat; Chao, Tsu-Yi; Shahidi, Mehdi; Cong, Xiuyu Julie; Lorence, Robert M.; Yang, James Chih-Hsin |
| 國立成功大學 |
2012-05 |
Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial
|
Yang, James Chih-Hsin; Shih, Jin-Yuan; Su, Wu-Chou; Hsia, Te-Chun; Tsai, Chun-Ming; Ou, Sai-Hong Ignatius; Yu, Chung-Jen; Chang, Gee-Chen; Ho, Ching-Liang; Sequist, Lecia V.; Dudek, Arkadiusz Z.; Shahidi, Mehdi; Cong, Xiuyu Julie; Lorence, Robert M.; Yang, Pan-Chyr; Miller, Vincent A. |
| 國立臺灣大學 |
2012 |
Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial
|
Yang, James Chih-Hsin; Shih, Jin-Yuan; Su, Wu-Chou; Hsia, Te-Chun; Tsai, Chun-Ming; Ou, Sai-Hong Ignatius; Yu, Chung-Jen; Chang, Gee-Chen; Ho, Ching-Liang; Sequist, Lecia V.; Dudek, Arkadiusz Z.; Shahidi, Mehdi; Cong, Xiuyu Julie; Lorence, Robert M.; Yang, Pan-Chyr; Miller, Vincent A.; 楊志新; 楊泮池; 余忠仁; 施金元 |
| 國立臺灣大學 |
2012 |
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial
|
Miller, Vincent A.; Hirsh, Vera; Cadranel, Jacques; Chen, Yuh-Min; Park, Keunchil; Kim, Sang-We; Zhou, Caicun; Su, Wu-Chou; Wang, Mengzhao; Sun, Yan; Heo, Dae Seog; Crino, Lucio; Tan, Eng-Huat; Chao, Tsu-Yi; Shahidi, Mehdi; Cong, Xiuyu Julie; Lorence, Robert M.; Yang, James Chih-Hsin; 楊志新 |
| 國立成功大學 |
2009-09 |
BIBW 2992, a novel irreversible EGFR/HER2 tyrosine kinase inhibitor, in chemonaive patients with adenocarcinoma of the lung and activating EGFR mutations
|
Yang Chih-Hsin; Shih Jin-Yuan; Su Wu-Chou; Hsia Te-Chun; Ho Ching-Liang; Dudek, Arkadiusz Z.; Terlizzi, Elizabeth; Zhao Yihua M; Shahidi, Mehdi; Miller, Vincent A. |
显示项目 1-9 / 9 (共1页)
1
每页显示[10|25|50]项目
|
